Business News

Biogen Pays $75 Million for Pfizer’s Early-Stage Alzheimer’s Disease Drug Candidate

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and …

Read More »

Incyte Pays $750 Million Upfront for Rights to MorphoSys’ Investigational Cancer Drug

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) announced today that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys’ proprietary anti-CD19 antibody tafasitamab (MOR208) globally. Tafasitamab is an Fc-engineered antibody against CD19 currently …

Read More »

Axsome Enters License Agreement for Pfizer’s Phase 3 Fibromyalgia Candidate

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into an agreement with Pfizer Inc. (NYSE: PFE) for an exclusive U.S. license to Pfizer’s clinical and nonclinical data, …

Read More »

Janssen and Exonate Partner to Develop New Eye Drop for Treatment of Retinal Vascular Diseases

CAMBRIDGE, England, Jan. 13, 2020 /PRNewswire/ — Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development, LLC …

Read More »

Concerto HealthAI and Pfizer Expand Collaboration to Accelerate Real-World Evidence and AI Technologies for Additional Disease Areas

BOSTON, Jan. 10, 2020 /PRNewswire/ — Concerto HealthAI announced an expansion of their existing Precision Oncology collaboration with Pfizer Oncology to advance Concerto HealthAI’s use-case engineered Real-World Data (RWD) for an array of clinical development initiatives across breast, lung, prostate and renal cell carcinoma cancers that will drive innovative new …

Read More »

Lilly to Acquire Dermira for $1.1 Billion

INDIANAPOLIS and MENLO PARK, Calif., Jan. 10, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Dermira, Inc. (NASDAQ: DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions. The acquisition will expand Lilly’s immunology pipeline with …

Read More »

Evotec and Bayer Announce New Alliance Focusing on Drug Discovery for Polycystic Ovary Syndrome With Novel Targets From Celmatix

NEW YORK–(BUSINESS WIRE)–Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”). Under the terms of the agreement, both companies …

Read More »

Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These investigational agents have potential for use in HIV long-acting therapies for treatment and prevention, as …

Read More »

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

INGELHEIM AM RHEIN, Germany & SINGAPORE–(BUSINESS WIRE)–Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise …

Read More »

Xencor and Gilead Enter License Agreement for Use of XmAb Antibody Technologies in Investigational Agents for HIV

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a technology license agreement in which Gilead Sciences, Inc., will access Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for …

Read More »